Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lava Therapeutics N.V. (NQ: LVTX )

1.560 -0.040 (-2.50%)
Streaming Delayed Price Updated: 3:06 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lava Therapeutics N.V.

LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
From LAVA Therapeutics N.V.
Via Globe NewsWire
LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
From LAVA Therapeutics N.V.
Via Globe NewsWire
LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
From LAVA Therapeutics N.V.
Via Globe NewsWire
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
From LAVA Therapeutics N.V.
Via Globe NewsWire
LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
From LAVA Therapeutics N.V.
Via Globe NewsWire
LAVA Therapeutics Announces Appointment of New Directors to the Board
Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board 
From LAVA Therapeutics N.V.
Via Globe NewsWire
LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From LAVA Therapeutics N.V.
Via Globe NewsWire
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts 
From LAVA Therapeutics N.V.
Via Globe NewsWire
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
From LAVA Therapeutics N.V.
Via Globe NewsWire
LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
From LAVA Therapeutics N.V.
Via Globe NewsWire
LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
From LAVA Therapeutics N.V.
Via Globe NewsWire
LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer
From LAVA Therapeutics N.V.
Via Globe NewsWire
LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
From LAVA Therapeutics N.V.
Via Globe NewsWire
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223
LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development 
Via Spotlight Growth
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
From Seagen Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.